CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
Varenicline +1 moredrug
Likely dose
Varenicline 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02892110
NCT02892110Phase 2Completed
CompareCT.gov

Advancing Varenicline as a Treatment for Cannabis Use Disorder

Medical University of South Carolina·interventional·Posted Sep 8, 2016·Updated Dec 3, 2019

In Brief

A Phase 2 clinical trial evaluating Varenicline and Placebo for Substance Use Disorder. Completed, enrolled 72 participants across 1 site.

Detailed Summary

Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 8, 2016
Enrollment StartFeb 13, 2017
Primary CompletionNov 8, 2018
Study CompletionNov 27, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.8 years ago

Interventions

Vareniclinedrug

2 mg daily

Placebodrug

2 mg daily